Authors: Storm Johnson (Future Science Group)
New encapsulating technology for whole-cell vaccines stimulates enhanced immunogenicity against Escherichia coli in a mouse model, shaping the future of urinary tract infection (UTI) vaccines.
Recurrent UTIs may soon be a thing of the past as researchers develop a new encapsulating technology for whole-cell vaccines. Co-senior authors Nicole De Nisco and Jeremiah Gassensmith (both University of Texas; TX, USA) collaborated on an interdisciplinary project developing a whole-cell vaccine for UTIs. The group demonstrated how their whole-cell bacteria encapsulated in a metal–organic framework (MOF) enhances antibody production in mice and provides a promising alternative to antibiotics and standard inactivated vaccines.